Mikey's campaign

Mikey's story 

Mikey is a playful, loving and cheeky little boy with a great sense of humour.  

In December 2017, when Mikey was just 20 months old and enjoying the build-up to Christmas, his parents noticed a lump in his tummy. After a trip to A&E, the doctors diagnosed his condition as stage 4 high-risk neuroblastoma. Further tests revealed that the tumour had grown from above his right kidney to across almost his entire abdomen. It had heavily infiltrated his bone marrow.  

Following immunotherapy and end of treatment scans, Mikey and his family flew to New York in April 2019 to access the bivalent vaccine clinical trial at Memorial Sloan Kettering Cancer Center with the hope of keeping the cancer away.  

Mikey’s campaign remains open in case he needs any potentially life-saving treatment in the future not available through the NHS, which could cost hundreds of thousands of pounds. 

Treatment so far 

Mikey was started on a gruelling induction chemotherapy schedule on Christmas Eve 2017, receiving eight cycles of treatment every ten days. He responded well to the initial treatment and then went on to battle his way through a complex eight-and-a-half-hour surgery to remove the remainder of the tumour.  

That was followed by high-dose chemotherapy with stem cell transplant, radiotherapy and immunotherapy treatment. Throughout his treatment, he has had to endure numerous blood transfusions, general anaesthetics, nose tube insertions, injections and antibiotics to fight infections. Amazingly, he has remained in high spirits keeping everyone entertained with his endless humour and cheeky personality.  

At the start of 2019, Mikey received clear end-of-frontline treatment scans and the family flew to New York to access a vaccine clinical trial designed to help stop his cancer from returning.  

_{Solving Kids' Cancer UK's children's fundraising campaigns} 

_{Funds raised will go towards helping Mikey and his family. If Mikey no longer needs the funds or is in remission five years post the end of successful treatment, the funds will be used to support other children and families affected by neuroblastoma through our activities. For children with high-risk neuroblastoma, like Mikey, the survival rate is much lower than other childhood cancers. Upon relapse, this rate reduces even further.}